Stock SANTARUS, INC.
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

News Santarus, Inc.

Equities

US8028173040

End-of-day quote Nasdaq
Other stock markets
- USD - Intraday chart for Santarus, Inc.
2013 The Ryland Group, Inc. : Dow, S&P 500 end higher for fifth straight week; financials lead RE
2013 Santarus, Inc. : Salix bolsters gastro drug line-up with $2.6 billion Santarus buy RE

Summary

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Santarus, Inc. : Relocation Plans, Patient Enrollment, Management Appointments, and Price Movements - Research Report on HCA Holdings, Opko Health, Santarus, Coronado, and Idera
PR
Santarus, Inc. : Santarus Announces Availability of Amended Tender Offer Materials
BU
Santarus, Inc. : Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis
BU
Santarus, Inc. : Ryan & Maniskas, LLP Announces Investigation of Santarus, Inc.
PR
The Ryland Group, Inc. : Dow, S&P 500 end higher for fifth straight week; financials lead
RE
Santarus, Inc. : Law Firm Kirby McInerney LLP Investigating Potential Claims on Behalf of Santarus, Inc. Stockholders
BU
Santarus, Inc. : Law Offices of Howard G. Smith Announces Investigation of Santarus Inc.
BU
Santarus, Inc. : Investor Alert: Holzer Holzer & Fistel, LLC Announces Investigation into the Proposed Buyout of Santarus, Inc.
BU
Santarus, Inc. : Shareholder Rights Law Firm Johnson & Weaver, LLP Announces Investigation of the Santarus, Inc. Proposed Acquisition by Salix Pharmaceuticals, Ltd.
BU
Santarus, Inc. : Law Firm Brower Piven Announces Investigation of Santarus, Inc. Proposed Buyout
BU
Santarus, Inc. : Santarus and Pharming Announce New Data from Open-Label Repeat Treatment Study with RUCONEST (Recombinant Human C1 Esterase Inhibitor)
PU
Santarus, Inc. : Salix bolsters gastro drug line-up with $2.6 billion Santarus buy
RE
Santarus, Inc. : Santarus Reports Third Quarter 2013 Financial Results
BU
Santarus, Inc. : Salix Pharmaceuticals to Acquire Santarus
BU
Santarus, Inc. : Acquisitions, Financial Results, Clinical Trial Applications, and Upcoming Earnings Schedules - Research Report on Illumina, DENTSPLY, Alnylam, Sirona, and Santarus
PR
Santarus, Inc. : Santarus to Hold Third Quarter 2013 Financial Results Conference Call on November 7
BU
Santarus, Inc. : Santarus Announces Presentation of SAN-300 Phase I Data at 2013 American College of Rheumatology Annual Meeting
BU
Santarus, Inc. : Santarus Announces Presentation of Phase III Data for Rifamycin SV MMX in Travelers' Diarrhea
BU
Santarus, Inc. : Pre-Market Review: Isis Pharmaceuticals Inc., Community Health Systems Inc., Quest Diagnostics Inc., and Santarus Inc.
PR
Santarus, Inc. : Santarus to Present at September Investment Conferences
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. Stock
  4. News Santarus, Inc.